Ophthalmology Doctors in Bluffton, SC Accepting Medicare

5 Ophthalmology doctors found. Showing 1 - 5

Dr. David Andrew Hunter, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10 William Pope Dr, Bluffton, SC 29909 Phone: 843-842-2020    Fax: 843-705-1512

David J Remigio, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 29 Plantation Park Dr, Bluffton, SC 29910 Phone: 843-757-9661    Fax: 843-757-9665

Dr. Scott Michael Anfinson, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 8 Arley Way, Suite 100, Bluffton, SC 29910 Phone: 843-815-5436    Fax: 843-815-7197

Dr. Mark T Goulas, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 23 Plantation Park Dr Ste 401, Bluffton, SC 29910 Phone: 843-815-5454    Fax: 843-757-9665

Dr. Erin Pauline Benjamin, D.O. Ophthalmology - Pediatric Ophthalmology and Strabismus Specialist Medicare: Accepting Medicare Assignments Practice Location: 23 Plantation Park Dr Ste 401, Bluffton, SC 29910 Phone: 845-815-5454    Fax: 843-757-9665

News Archive

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

Valensa International (Orlando, FL USA) announced today that it has initiated a broad out licensing effort for University of Illinois patent (US 5,527,533 and its foreign equivalents) for the use of the astaxanthin in eye healthcare dietary supplement applications.

Link between mood and food

People feeling sad tend to eat more of less-healthy comfort foods than when they feel happy, finds a new study co-authored by a Cornell food marketing expert. However, when nutritional information is available, those same sad people curb their hedonistic consumption. But happier people don't.

GABA corrects both known causes of Type 1 diabetes

A chemical produced by the same cells that make insulin in the pancreas prevented and even reversed Type 1 diabetes in mice, researchers at St. Michael's Hospital have found.

Analysis of the Phase I/II clinical trial of HIV drug candidate PA-457

V.I. Technologies (Vitex) and collaborators at the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, today presented a detailed analysis of the Phase I/II clinical trial of its HIV drug candidate PA-457 at the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil.

Read more Medical News

› Verified 4 days ago